

Sensus Healthcare Awarded 2017 Technology Leader of the Year for Disruptive Technology from Greater Miami Chamber of Commerce

BOCA RATON, Fla., May 24, 2017 /PRNewswire/ -- [Sensus Healthcare, Inc.](#) (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions, such as keloids with Superficial Radiotherapy (SRT), has been awarded the 2017 Technology Leader of the Year for the Disruptive Technology category by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the Company's proprietary, FDA-cleared, low-energy X-ray radiation technology known as SRT, which has effectively and safely treated oncological and non-oncological skin conditions in thousands of patients to date.

"At Sensus, we are committed to providing the best, most innovative technologies to treat patients, both nationally and internationally, who suffer from non-melanoma skin cancer and keloids. We are proud to be the recipient of this prestigious award for Disruptive Technology," said Joe Sardano, CEO, Sensus Healthcare. "This recognition is a testament to the power of SRT and its unique ability to provide safe, non-surgical treatments that are fast, painless and proven effective."

The Technology Leaders of the Year Awards is an annual program that honors the individuals, organizations and companies that are leaders in the South Florida technology community. Presented by the Greater Miami Chamber of Commerce, award recipients are honored for the effective use of technology to improve business performance or to develop new markets or products and have made significant positive contributions to the South Florida technology community.

About Sensus

Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit <http://www.sensushealthcare.com>.

Public Relations:

Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
Phone: 212-896-1241 / 212-896-1206
Email: ckasunich@kcsa.com / nopich@kcsa.com

SOURCE Sensus Healthcare, Inc.

<http://investors.sensushealthcare.com/2017-05-24-Sensus-Healthcare-Awarded-2017-Technology-Leader-of-the-Year-for-Disruptive-Technology-from-Greater-Miami-Chamber-of-Commerce>